ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinical characteristics and prognostic value of theKRAS G12Cmutation in Chinese non-small cell lung cancer patients

Liu, Si-Yang; Sun, Hao; Zhou, Jia-Ying; Jie, Guang-Ling; Xie, Zhi; Shao, Yang; Zhang, Xian; Ye, Jun-Yi; Chen, Chun-Xiang; Zhang, Xu-Chao; Zhou, Qing; Yang, Jin-Ji; Wu, Yi-Long*
Biomarker Research2020-6-25DOI: 10.1186/s40364-020-00199-z
38被引22阅读
引用收藏
分享

摘要

Background TheKRASmutation is the second most common genetic variant in Chinese non-small cell lung cancer (NSCLC) patients. At the 2019th World Conference of Lung Cancer, theKRAS G12C-specific inhibitor AMG510 showed promising results in the phase I clinical trial. However, the frequency, clinical characteristics, and prognostic significance of theKRAS G12Cmutation in Chinese NSCLC patients are rarely reported. Methods Next-generation sequencing was used to confirm theKRASmutation status in 40,804 NSCLC patients from multiple centers (mCohort). Survival data were collected retrospectively from 1456 patients at one of the centers, the Guangdong Lung Cancer Institute (iCohort). Results In the mCohort, 3998 patients (9.8%) were confirmed to harbor aKRASmutation, of whom 1179 (29.5%) had theG12Csubtype. In the iCohort, 130 NSCLC patients (8.9%) had aKRASmutation and 42 (32.3%) had theG12Csubtype. TheG12Csubgroup included more male patients (85.2% vs 67.4%,P < 0.0001) and more smokers (76.2% vs 53.4%,P = 0.02) than did the non-G12Csubgroup. Both theKRASmutation group andKRAS G12Cmutation subgroup were associated with a shorter median overall survival (OS) than wildtype tumors (15.1 vs 26.7 months, hazard ratio [HR](KRAS) = 1.50,P = 0.002; 18.3 vs 26.7 months, HRG12C = 1.66,P = 0.007). In Cox regression analysis, smoking (HR = 1.39,P = 0.05) and stage IV disease (HR = 2.72,P < 0.001) remained as independent predictors of shorter OS. Both theKRASmutation (HR = 1.30,P = 0.07) andKRAS G12Cmutation (HR = 1.47,P = 0.07) reached borderline significance. Conclusions In the largest sample used thus for, our study found that approximately 10% of Chinese NSCLC patients hadKRASmutations. Of these, nearly 30% harbored theKRAS G12Cmutation subtype, which was most common in male smokers. TheKRAS G12Cmutation is a biomarker of poor prognosis in Chinese NSCLC patients, which could potentially be improved byG12C-specific inhibitors in the future. (296 words)

学科与关键词

关键词
KRASmutationKRAS G12CmutationPrognosisNon-small cell lung cancerChinese patients
相关
加载中…
  • KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy
    Guan Ji lin*; Zhong Wen zhao; An She juan; Yang Jin ji; Su Jian; Chen Zhi hong; Yan Hong hong; Chen Zhi yong; Huang Zhi min; Zhang Xu chao; Nie Qiang; Wu Yi longAnnals of Surgical Oncology, 2013, 20(4): 1381-1388.被引 23
  • Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
    Li, Jia-Xin; Li, Run-Ze; Ma, Lin-Rui; Wang, Peng; Xu, Dong-Han; Huang, Jie; Li, Li-Qi; Tang, Ling; Xie, Ying; Leung, Elaine Lai-Han*; Yan, Pei-Yu*Frontiers in Pharmacology, 2022, 13: 875330.被引 2
  • The distribution of genetic mutations correlated with resistance to KRASG12C inhibitors in Chinese patients with lung cancer.
    Lin, Shengcheng; Ma, Kai; Xu, Yafei; Liu, Xinyi; Huang, Xiaochun; Huang, MengliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
查看全部 →

发表信息

论文状态
公开发表
期刊
Biomarker Research
发表日期
2020-06-25
卷期
第 8 卷, 第 1 期
页码
22
DOI
10.1186/s40364-020-00199-z
期刊收录
NSL.SCIE
期刊等级
3区
成果收录
SCIE
资助标注
National Key R&D Program of China [2016YFC1303800]; Special Fund of Public Interest by National Health and Family Control Committee [201402031]; Key Lab System Project of Guangdong Science and Technology Department [2012A061400006, 2017B030314120]; Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2012A061400006, 2017B030314120]; Health Collaborative Innovation Major Project from Guangzhou Science and Technology Bureau [201400000001-2]

作者

  • L

    Liu, Si-Yang (第一作者)

  • S

    Sun, Hao

查看全部 13 位作者收起作者
  • Z

    Zhou, Jia-Ying

  • J

    Jie, Guang-Ling

  • X

    Xie, Zhi

  • S

    Shao, Yang

  • Z

    Zhang, Xian

  • Y

    Ye, Jun-Yi

  • C

    Chen, Chun-Xiang

  • Z

    Zhang, Xu-Chao

  • Z

    Zhou, Qing

  • Y

    Yang, Jin-Ji

  • W

    Wu, Yi-Long (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417